Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02981368 · OUTCOME

Negative Predictive Value (NPV) of 18F-DCFPyL PET/CT to Predict Prostate Cancer Within the Prostate Gland of High Risk Prostate Cancer Participants (Cohort A)

Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer · Source last updated 2021-08-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.

What was measured

Negative Predictive Value (NPV) is based on a 18F-DCFPyL PET/CT image result and a histopathology result. The NPV is determined from the number of true negatives (negative 18F-DCFPyL image and a negative histopathology result for prostate cancer) divided by the number of participants with a negative 18F-DCFPyL image.

Analysis population: The Evaluable Set of high risk prostate cancer participants (Cohort A) includes those who received 18F-DCFPyL, had a prostatectomy or lymphadenectomy, and provided a 18F-DCFPyL PET/CT image result and a corresponding histopathology result.

Groups in this outcome

High Risk Prostate Cancer (Cohort A)

High risk prostate cancer participants planned for radical prostatectomy with pelvic lymph node dissection were enrolled to receive a single dose of 9 mCi (333 MBq) IV injection of 18F-DCFPyL, followed by PET/CT imaging acquired 1-2 hours post-PyL injection.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
High Risk Prostate Cancer (Cohort A)247

Reported measurements

Central Reader 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
High Risk Prostate Cancer (Cohort A)0Not reportedNANANPV was 0 - no participant had negative histology in the prostate.
Central Reader 2
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
High Risk Prostate Cancer (Cohort A)0Not reportedNANANPV was 0 - no participant had negative histology in the prostate.
Central Reader 3
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
High Risk Prostate Cancer (Cohort A)0Not reportedNANANPV was 0 - no participant had negative histology in the prostate.
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        NPV was 0 - no participant had negative histology in the prostate.
        group Id
        OG000
        lower Limit
        NA
        upper Limit
        NA
        value
        0
    title
    Central Reader 1
  2. categories
    1. measurements
      1. comment
        NPV was 0 - no participant had negative histology in the prostate.
        group Id
        OG000
        lower Limit
        NA
        upper Limit
        NA
        value
        0
    title
    Central Reader 2
  3. categories
    1. measurements
      1. comment
        NPV was 0 - no participant had negative histology in the prostate.
        group Id
        OG000
        lower Limit
        NA
        upper Limit
        NA
        value
        0
    title
    Central Reader 3
denoms
  1. counts
    1. group Id
      OG000
      value
      247
    units
    Participants
description
Negative Predictive Value (NPV) is based on a 18F-DCFPyL PET/CT image result and a histopathology result. The NPV is determined from the number of true negatives (negative 18F-DCFPyL image and a negative histopathology result for prostate cancer) divided by the number of participants with a negative 18F-DCFPyL image.
dispersion Type
95% Confidence Interval
groups
  1. description
    High risk prostate cancer participants planned for radical prostatectomy with pelvic lymph node dissection were enrolled to receive a single dose of 9 mCi (333 MBq) IV injection of 18F-DCFPyL, followed by PET/CT imaging acquired 1-2 hours post-PyL injection.
    id
    OG000
    title
    High Risk Prostate Cancer (Cohort A)
param Type
NUMBER
population Description
The Evaluable Set of high risk prostate cancer participants (Cohort A) includes those who received 18F-DCFPyL, had a prostatectomy or lymphadenectomy, and provided a 18F-DCFPyL PET/CT image result and a corresponding histopathology result.
reporting Status
POSTED
time Frame
Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.
title
Negative Predictive Value (NPV) of 18F-DCFPyL PET/CT to Predict Prostate Cancer Within the Prostate Gland of High Risk Prostate Cancer Participants (Cohort A)
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice